Fusion Pharmaceuticals Stock EBITDA
Fusion Pharmaceuticals fundamentals help investors to digest information that contributes to Fusion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Fusion Stock. The fundamental analysis module provides a way to measure Fusion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fusion Pharmaceuticals stock.
Fusion |
Fusion Pharmaceuticals Company EBITDA Analysis
Fusion Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Fusion Pharmaceuticals EBITDA | (97.89 M) |
Most of Fusion Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fusion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Fusion Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (97.89 Million). This is 111.16% lower than that of the Biotechnology sector and 197.73% lower than that of the Health Care industry. The ebitda for all United States stocks is 102.51% higher than that of the company.
Fusion EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fusion Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fusion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Fusion Pharmaceuticals by comparing valuation metrics of similar companies.Fusion Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Fusion Fundamentals
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (54.04) % | |||
| Current Valuation | 1.69 B | |||
| Shares Outstanding | 85.06 M | |||
| Shares Owned By Insiders | 0.46 % | |||
| Shares Owned By Institutions | 86.80 % | |||
| Number Of Shares Shorted | 3.06 M | |||
| Price To Book | 8.13 X | |||
| Price To Sales | 874.50 X | |||
| Revenue | 2.07 M | |||
| Gross Profit | (57.43 M) | |||
| EBITDA | (97.89 M) | |||
| Net Income | (94.9 M) | |||
| Cash And Equivalents | 198.42 M | |||
| Cash Per Share | 4.57 X | |||
| Total Debt | 50.33 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 17.89 X | |||
| Book Value Per Share | 2.85 X | |||
| Cash Flow From Operations | (81.8 M) | |||
| Short Ratio | 6.22 X | |||
| Earnings Per Share | (1.40) X | |||
| Target Price | 21.14 | |||
| Number Of Employees | 101 | |||
| Beta | -0.69 | |||
| Market Capitalization | 1.83 B | |||
| Total Asset | 285.84 M | |||
| Retained Earnings | (376.76 M) | |||
| Working Capital | 227.18 M | |||
| Net Asset | 285.84 M |
Pair Trading with Fusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Oracle could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oracle when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oracle - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oracle to buy it.
The correlation of Oracle is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oracle moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oracle moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oracle can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |